---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Use and Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in the Treatment of Cancer"
date: 2026-02-05 19:01:46 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-26430
original_published: 2022-12-06 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Use and Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in the Treatment of Cancer

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** December 06, 2022 00:00 UTC
**Document Number:** 2022-26430

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Supplementary Information section of this notice to Drug Development and Filing Consulting, LLC located in Maryland, USA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/12/06/2022-26430/prospective-grant-of-an-exclusive-patent-license-use-and-development-of-rab13-and-net1-targeting)
- API: https://www.federalregister.gov/api/v1/documents/2022-26430

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
